IP Library Granted Patent US 8,741,341
Granted Patent B2
US 8,741,341 · App. 13/847,875 · Granted Jun 3, 2014

Manufacturing and packaging room temperature stable dronabinol capsules

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,341
App. No.
13/847,875
Granted
Jun 3, 2014
Kind
B2
Abstract

The invention provides a method of manufacturing and packaging a room temperature stable cannabinoid dosage in an oil-based carrier, wherein the method employs the use of blister packaging and an inert gas atmosphere during blister packaging. The invention also provides a room temperature stable cannabinoid dosage prepared by the methods of the invention.

Claims (15)

1. A method of manufacturing and packaging a cannabinoid dosage, consisting of the following steps:

a) preparing a fill solution with a desired concentration of a cannabinoid in a liquid carrier;

b) encapsulating said fill solution in capsules;

c) packaging said capsules in a closed packaging system; and

d) removing atmospheric air from the capsules,

wherein the removing of atmospheric air consists solely of purging said packaging system with an inert gas, and wherein said packaging system provides a room temperature stable product.

2. The method of claim 1 , wherein the packaging system is a blister package.

3. The method of claim 2 wherein the blister package is constructed of material that minimizes exposure to moisture and air.

4. The method of claim 1 , wherein the cannabinoid is dronabinol.

5. The method of claim 1 , wherein the liquid carrier is oil-based carrier.

6. The method of claim 5 , wherein the oil-based carrier is sesame oil.

7. The method of claim 1 , wherein the capsules are soft gelatin capsules.

8. The method of claim 1 , wherein the inert gas is nitrogen.

9. The method of claim 1 , wherein the desired cannabinoid concentration is about 1-10% w/w.

10. The method of claim 9 wherein the desired concentration is about 1.5-6.5% w/w.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 3, 2016
From: INSYS PHARMA, INC.
To: INSYS DEVELOPMENT COMPANY, INC.
Reel/Frame 037652/0049 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY'S DATA PREVIOUSLY RECORDED ON REEL 031050 FRAME 0064. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Sep 11, 2014
From: GOSKONDA, VENKAT; CHAVAN, ASHOK; CRISMAN, SCOTT; LOPEZ, CRYSTAL; AMANCHA, KIRAN
To: INSYS PHARMA, INC.
Reel/Frame 033717/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 21, 2013
From: GOSKONDA, VENKAT R.; CHAVAN, ASHOK; AMANCHA, KIRAN; CRISMAN, SCOTT; LOPEZ, CRYSTAL
To: INSYS THERAPEUTICS, INC.
Reel/Frame 031050/0064 →